ZA938171B - Conjugate vaccine against group B Streptococcus. - Google Patents

Conjugate vaccine against group B Streptococcus.

Info

Publication number
ZA938171B
ZA938171B ZA938171A ZA938171A ZA938171B ZA 938171 B ZA938171 B ZA 938171B ZA 938171 A ZA938171 A ZA 938171A ZA 938171 A ZA938171 A ZA 938171A ZA 938171 B ZA938171 B ZA 938171B
Authority
ZA
South Africa
Prior art keywords
streptococcus
vaccine against
conjugate vaccine
against group
group
Prior art date
Application number
ZA938171A
Inventor
James L Michel
Dennis L Kasper
Frederick M Ausubel
Lawrence C Madoff
Original Assignee
Gen Hospital Corp
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Brigham & Womens Hospital filed Critical Gen Hospital Corp
Publication of ZA938171B publication Critical patent/ZA938171B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
ZA938171A 1992-11-02 1993-11-02 Conjugate vaccine against group B Streptococcus. ZA938171B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96886692A 1992-11-02 1992-11-02

Publications (1)

Publication Number Publication Date
ZA938171B true ZA938171B (en) 1995-03-07

Family

ID=25514876

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA938171A ZA938171B (en) 1992-11-02 1993-11-02 Conjugate vaccine against group B Streptococcus.

Country Status (14)

Country Link
EP (1) EP0669985A1 (en)
JP (1) JPH08505282A (en)
KR (1) KR100349331B1 (en)
AU (1) AU689452B2 (en)
CA (1) CA2146926A1 (en)
FI (1) FI951979A (en)
HU (1) HU220198B (en)
IL (1) IL107458A0 (en)
NO (1) NO951629L (en)
NZ (1) NZ258684A (en)
PL (1) PL177302B1 (en)
RU (1) RU2209247C2 (en)
WO (1) WO1994010317A2 (en)
ZA (1) ZA938171B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015889A (en) * 1993-03-19 2000-01-18 Gunnar Lindahl Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
EP1100920A2 (en) * 1998-07-27 2001-05-23 Microbial Technics Limited Nucleic acids and proteins from group b streptococcus
US7098182B2 (en) 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
KR100866170B1 (en) * 1998-12-22 2008-10-30 이머전트 프로덕트 디벨로프먼트 유케이 리미티드 Outer surface proteins, their genes and their use
GB9910375D0 (en) 1999-05-05 1999-06-30 Lindahl Gunnar Vaccine composition
ES2382893T3 (en) * 2000-10-13 2012-06-14 Id Biomedical Corporation BVH-A2 and BVH-3 antigens of group B streptococcus
AU2004220590B2 (en) 2003-03-07 2010-02-18 Inhibitex, Inc. Polysaccharide - Staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
CN101855238B (en) 2007-04-16 2014-09-17 米纳瓦克斯有限责任公司 Fusion protein vaccine
WO2010022961A1 (en) * 2008-08-28 2010-03-04 Novartis Ag Cell surface display of polypeptide isoforms by stop codon readthrough
CA3001433A1 (en) 2015-10-21 2017-04-27 Minervax Aps Immunogenic fusion protein
WO2017114655A1 (en) 2015-12-30 2017-07-06 Minervax Aps Immunogenic complex for eliciting protective immunity against group b streptococcus
CA3066020A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
EP4061412A1 (en) 2019-11-22 2022-09-28 GlaxoSmithKline Biologicals S.A. Dosage and administration of a bacterial saccharide glycoconjugate vaccine
EP4066854A1 (en) 2021-03-29 2022-10-05 MinervaX Immunogenic fusion protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302887B1 (en) * 1986-04-16 1994-06-22 The Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines, and methods of manufacture
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp Conjugate vaccine formed from a polysaccharide and a c protein of b-streptococcus

Also Published As

Publication number Publication date
AU5665494A (en) 1994-05-24
EP0669985A1 (en) 1995-09-06
HUT70981A (en) 1995-11-28
IL107458A0 (en) 1994-02-27
WO1994010317A2 (en) 1994-05-11
NZ258684A (en) 1997-04-24
FI951979A (en) 1995-06-29
WO1994010317A3 (en) 1994-07-07
PL308555A1 (en) 1995-08-21
JPH08505282A (en) 1996-06-11
NO951629L (en) 1995-07-03
AU689452B2 (en) 1998-04-02
NO951629D0 (en) 1995-04-28
RU2209247C2 (en) 2003-07-27
PL177302B1 (en) 1999-10-29
CA2146926A1 (en) 1994-05-11
HU220198B (en) 2001-11-28
FI951979A0 (en) 1995-04-26
KR100349331B1 (en) 2003-01-06
KR950704492A (en) 1995-11-20

Similar Documents

Publication Publication Date Title
EP0634459A3 (en) Formulations.
AU6858391A (en) Bundle tie
CZ197595A3 (en) Vaccine preparations
ZA926733B (en) 1,2-Dihydro-2-oxopyridines.
EP0604748A3 (en) Trocar sleeve.
ZA938171B (en) Conjugate vaccine against group B Streptococcus.
ZA937034B (en) Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
EP0572808A3 (en) Antiblocage-system.
EP0468714A3 (en) Peptide-polysaccharide-protein conjugate vaccines
ZA927999B (en) Thickening agents.
EP0595970A4 (en) Improved vaccine.
EP0584212A4 (en) Liposomal polysaccharide vaccines.
EP0592354A3 (en) Vacuum-centrifuge.
ZA933848B (en) Pyridyl-1,2,5-oxadiazolecarboxamide-2-oxides
AU4970193A (en) IPNV vaccine
GB9320943D0 (en) Peptide-protein conjugate vaccines having anionic spacers
AU5626998A (en) Conjugate vaccine against group B Streptococcus
ZA939564B (en) Vaccines.
EP0681480A4 (en) Recognin vaccines.
SG48106A1 (en) Pneumococcal polyaccharide conjugate vaccine
ZA93236B (en) Babesial rhoptry antigens.
EP0647139A4 (en) ADHESIN-OLIGOSACCHARIDE CONJUGATE VACCINE FOR -i(HAEMOPHILUS INFLUENZAE).
ZA967198B (en) Vaccines.
GB9108748D0 (en) Conjugate
EP0644890A4 (en) Oligonucleotide-polyamide conjugates.